SCHEMBL20567700

SCHEMBL20567700

Cc1ccc(CC(=O)O)c(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.59
PTGS2 P35354 4/20 0.55
MAPT P10636 3/20 0.50
ALOX15 P16050 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ABCB11 O95342 1/20 0.49
PTGS1 P23219 1/20 0.49
PPARG P37231 1/20 0.49
NR1I3 Q14994 1/20 0.49
DGAT1 O75907 1/20 0.47
CAMK2A Q9UQM7 3/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
AKR1B1 P15121 1/20 0.42
CA2 P00918 1/20 0.42
CXCL8 P10145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8672048 0.85 SRC (0.44) SRCPTGS2MAPTALOX15SMN1; SMN2
SCHEMBL8657001 0.85 SRC (0.42) SRCPTGS2SMN1; SMN2ABCB11PTGS1
SCHEMBL5236792 0.85 PTGS2 (0.59) SRCPTGS2MAPTALOX15SMN1; SMN2
SCHEMBL25382106 0.83 ICMT (0.43) SRCPTGS2SMN1; SMN2DGAT1
SCHEMBL12258207 0.82 SRC (0.65) SRCPTGS2MAPTALOX15SMN1; SMN2
SCHEMBL8365787 0.81 NPSR1 (0.53) SRCMAPTSMN1; SMN2PPARGKDM4E
SCHEMBL31204453 0.81 SRC (0.40) SRCPTGS2MAPTSMN1; SMN2ABCB11
SCHEMBL473923 0.81 GRIK1 (0.46) DGAT1CAMK2AGAAAKR1B1CA2
SCHEMBL29899638 0.81 GRIK1 (0.46) DGAT1CAMK2AGAAAKR1B1CA2
SCHEMBL24543280 0.80 PPARG (0.52) SMN1; SMN2PPARGMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059186-A1 N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-03-21 WO disclosed
US-11702396-B2 Hydrophobic compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-07-18 US disclosed
US-20180338980-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702396-B2 Hydrophobic compounds for optically active devices UACA, CRYZ, TRPA1 SRC 4155/4885PTGS2 1531/4885MAPT 681/4885
US-20180338980-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 SRC 867/4885PTGS2 2521/4885MAPT 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.